An observational study in Human Papillomavirus Infection, sponsored by Bilecik Seyh Edebali Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Bilecik Seyh Edebali Universitesi · Observational
This qualitative phenomenological study aims to explore the lived experiences of women diagnosed with human papillomavirus (HPV) infection. The study will examine women's emotional responses to the diagnosis, its perceived effects on daily life, sexual life and partner relationships, their experiences of disclosing the diagnosis, and their information and support needs. Eligible women diagnosed with HPV infection will participate in individual semi-structured interviews. The interview data will be analyzed thematically to identify common themes reflecting participants' experiences and perceptions.
This study is designed as a qualitative phenomenological study to gain an in-depth understanding of the lived experiences of women diagnosed with HPV infection. Participants will be adult women with a confirmed HPV diagnosis who meet the eligibility criteria and provide written informed consent.
Data will be collected through individual face-to-face semi-structured interviews. The interview guide explores participants' experiences from the time of HPV diagnosis, emotional responses, perceived effects on daily and sexual life, partner relationships and disclosure experiences, concerns regarding future health, experiences with healthcare professionals, and perceived information and support needs. Interviews are expected to last approximately 30-45 minutes and will be audio-recorded with participants' permission.
Data collection will continue until data saturation is achieved, with approximately 15-20 participants anticipated. Interview recordings will be transcribed and analyzed thematically. Participant identities will be protected through coding, and personally identifying information will not be included in the analysis or reporting of the findings.
576 studies on the registry are indexed under Papillomavirus Infections; 132 are open to participants now.
This study's planned enrollment of 15 is below the median of 490 across 157 observational studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →Bilecik Seyh Edebali Universitesi is the lead sponsor of 62 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult women aged 18 years or older with a confirmed HPV infection who meet the eligibility criteria and voluntarily agree to participate in the study. Participants will be recruited among women evaluated at the study center and will undergo individual semi-structured interviews regarding their lived experiences following HPV diagnosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult women aged 18 years or older with a confirmed HPV infection who meet the eligibility criteria and provide written informed consent. Participants will take part in individual semi-structured interviews exploring their lived experiences following HPV diagnosis.
Other: Semi-Structured Interview
Participants will take part in an individual face-to-face semi-structured interview exploring their lived experiences following HPV diagnosis, including emotional responses, daily and sexual life, partner relationships, disclosure experiences, future health concerns, experiences with healthcare professionals, and information and support needs. Interviews are expected to last approximately 30-45 minutes and will be audio-recorded with participants' permission.
Lived Experiences of Women Diagnosed With HPV Infection
Participants' lived experiences following HPV diagnosis will be explored through individual semi-structured interviews. Interview transcripts will be analyzed thematically to identify themes related to emotional responses, daily and sexual life, partner relationships, disclosure experiences, future health concerns, interactions with healthcare professionals, and information and support needs.
Time frame: At least 4 weeks after HPV diagnosis, following the initial acute adjustment period, during a single 30-45-minute semi-structured interview.
Plan to share: No — Individual participant data will not be publicly shared due to the qualitative nature of the study and the potential risk of identifying participants from interview data. Data will be kept confidential and used only for the purposes of this study.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 53 non-industry observational studies under Papillomavirus Infections, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 92. This study's planned 3 months is below that.
Counting every sponsor, half of 66 studies reached it within 46 months; a quarter within 24 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bilecik Seyh Edebali Universitesi